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VIP36 functions as a transport lectin for trafficking certain
highmannose type glycoproteins in the secretory pathway.Here
we report the crystal structure of VIP36 exoplasmic/luminal
domain comprising a carbohydrate recognition domain and a
stalk domain.The structures ofVIP36 in complexwithCa2 and
mannosyl ligands are also described. The carbohydrate recogni-
tion domain is composed of a 17-stranded antiparallel -sand-
wich and binds one Ca2 adjoining the carbohydrate-binding
site. The structure reveals that a coordinated Ca2 ion orients
the side chains of Asp131, Asn166, and His190 for carbohydrate
binding. This result explains the Ca2-dependent carbohydrate
binding of this protein. TheMan--1,2-Man--1,2-Man, which
corresponds to the D1 arm of high mannose type glycan, is rec-
ognized by eight residues through extensive hydrogen bonds.
The complex structures reveal the structural basis for highman-
nose type glycoprotein recognition by VIP36 in a Ca2-depend-
ent and D1 arm-specific manner.
In eukaryotic cells, post-translational modification of secreted
proteins and intracellular protein transport between organelles
are ubiquitous features. One of the most studied systems is the
N-linked glycosylation pathway in the synthesis of secreted gly-
coproteins (1–3). The N-linked glycoproteins are subjected to
diverse modifications and are transported through the endo-
plasmic reticulum (ER)3 via the Golgi apparatus to their final
destinations inside and outside of the cell. Incorporation of the
cargo glycoproteins into the transport vesicles is mediated by
transmembrane cargo receptors, which have been identified as
intracellular lectins. For example, mannose 6-phosphate recep-
tor (4) functions as a cargo receptor for lysosomal proteins in
the trans-Golgi network, whereas ER-Golgi intermediate com-
partment (ERGIC)-53 (5, 6) and its yeast orthologs Emp46/47p
(7) are transport lectins for glycoproteins that are transported
out of the ER.
VIP36, vesicular-integral protein of 36 kDa, was originally
isolated from Madin-Darby canine kidney cells as a compo-
nent of detergent-insoluble, glycolipid-enriched complexes
containing apical marker (8). Confocal and immunoelectron
microscopic experiments have suggested that VIP36 is dis-
tributed by either the pre-Golgi secretory pathway (9–11) or
post-Golgi pathway (8, 12). Furthermore we showed that
VIP36 is involved in intracellular transport, in the secretion
of glycoproteins (e.g. clusterin) from polarized Madin-Darby
canine kidney cells (13), and in the secretion of -amylase
from rat parotid glands (14). Taken together, VIP36 appears
to play significant roles not only in vesicular transport from
the ER to the Golgi complex but also from the trans-Golgi
network to the plasma membrane.
The exoplasmic/luminal domain of VIP36 as well as the
luminal domain of ERGIC-53 and Emp46/47p share homology
with L (leguminous)-type lectins and are thus identified as car-
bohydrate recognition domains (CRDs). It has been shown that
ERGIC-53 interacts with glycoproteins carrying high mannose
type glycan by endo--N-acetylglucosaminidase H treatment
(15–17) and binds glycoproteins in a Ca2- and pH-dependent
manner (18). We have previously found that VIP36 has high
affinity for high mannose type glycans containing Man--1,2-
Man residues in Man7–9(GlcNAc)2-Asn peptides (19). Kamiya
et al. (20) recently reported in detail the carbohydrate binding
properties of VIP36 assayed by frontal affinity chromatography.
This work suggested the Ca2 dependence of carbohydrate
binding and the specificity for the D1 arm, Man--1,2-Man--
1,2-Man residues, of high mannose type glycans (correspond-
ing to Man(D1)-Man(C)-Man(4); Fig. 1). In addition, using a
flow cytometry-based method, it was also demonstrated that
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VIP36 binds glycoproteins carrying high mannose type glycans
(21). These observations suggested that VIP36 is involved in the
transport of glycoproteins via high mannose type glycans.
Crystal structures of the CRDof rat ERGIC-53 in the absence
and presence of Ca2 have been determined, confirming its
structural similarity to the L-type lectins (22, 23). In these
reports, it was shown that the putative ligand-binding site of
ERGIC-53 is similar to the mannose-binding site of the L-type
lectins. Very recently, we reported the crystal structures of the
CRD of Ca2-independent K-bound Emp46p and the metal-
free form of Emp47p (24). To date, however, no structures of
transport lectins in complex with high mannose type glycans
have been determined. To investigate the structural basis of the
mechanism of high mannose type glycoprotein recognition by
VIP36, we determined crystal structures of the exoplasmic/lu-
minal domain of VIP36 alone and in complex with Ca2 and
mannose, Man--1,2-Man (termed Man2, which corresponds
to Man(D1)-Man(C), Man(C)-Man(4), Man(D2)-Man(A), or
Man(D3)-Man(B) of Man9(GlcNAc)2; Fig. 1), and Man--1,2-
Man--1,3-Man--1,4-GlcNAc (termed Man3GlcNAc, which
corresponds to Man(C)-Man(4)-Man(3)-GlcNAc(2); Fig. 1).
EXPERIMENTAL PROCEDURES
Synthesis of Man--1,2-Man--1,2-Man, Man--1,2-Man-
-1,3-Man, and Man--1,2-Man--1,6-Man—Couplings of
phenyl 3,4,6-tri-O-benzyl--D-thiomannopyranoside (i), phe-
nyl 2,4,6-tri-O-benzyl--D-thiomannopyranoside (ii), and phe-
nyl 2,3,4-tri-O-benzyl--D-thiomannopyranoside (iii) having
hydroxyl groups at the C-2, C-3, and C-6 positions (25) and
1,2-di-O-acetyl-3,4,6-tri-O-benzyl--D-mannopyranose (iv)
(26) were performed under conditions well established for
-mannosidation (trimethylsilyl trifluoromethanesulfonate/
CH2Cl2) to give phenyl 2-O-acetyl-3,4,6-tri-O-benzyl--D-
mannopyranosyl-(132)-3,4,6-tri-O-benzyl--D-thioman-
nopyranoside (v), phenyl 2-O-acet-
yl-3,4,6-tri-O-benzyl--D-manno-
pyranosyl-(133)-2,4,6-tri-O-ben-
zyl--D-thiomannopyranoside (vi),
and phenyl 2-O-acetyl-3,4,6-tri-O-
benzyl--D-mannopyranosyl-(136)-
2,3,4-tri-O-benzyl--D-thiomanno-
pyranoside (vii) (27), respectively.
Subsequent deacetylation of the
mannobioses (v, vi, and vii) gave
phenyl 3,4,6-tri-O-benzyl--D-
mannopyranosyl-(132)-3,4,6-tri-O-
benzyl--D-thiomannopyranoside
(viii), phenyl 3,4,6-tri-O-benzyl--D-
mannopyranosyl-(133)-2,4,6-tri-
O-benzyl--D-thiomannopyranoside
(ix), and phenyl 3,4,6-tri-O-benzyl--
D-mannopyranosyl-(136)-2,3,4-tri-
O-benzyl--D-thiomannopyranoside
(x) (27), respectively. Introduction of
thenon-reducing endof themannose
residue to the mannobioses (viii, ix,
and x) using 1-O-acetyl-2,3,4,6-tetra-
O-benzyl--D-mannopyranose (xi)
(28)was performed using the same -mannosidationmethod
to give phenyl 2,3,4,6-tetra-O-benzyl--D-mannopyranosyl-
(132)-3,4,6-tri-O-benzyl--D-mannopyranosyl-(132)-
3,4,6-tri-O-benzyl--D-thiomannopyranoside (xii), phenyl
2,3,4,6-tetra-O-benzyl--D-mannopyranosyl-(132)-3,4,6-
tri-O-benzyl--D-mannopyranosyl-(133)-2,4,6-tri-O-ben-
zyl--D-thiomannopyranoside (xiii), and phenyl 2,3,4,6-
tetra-O-benzyl--D-mannopyranosyl-(132)-3,4,6-tri-O-
benzyl--D-mannopyranosyl-(136)-2,3,4-tri-O-benzyl--
D-thiomannopyranoside (xiv), respectively. Finally complete
deprotection of synthesized mannotriose derivatives (xii, xiii,
and xiv) afforded -D-mannopyranosyl-(132)--D-mannopy-
ranosyl-(132)--D-mannopyranose, -D-mannopyranosyl-
(132)--D-mannopyranosyl-(133)--D-mannopyranose, and
-D-mannopyranosyl-(132)--D-mannopyranosyl-(136)-
-D-mannopyranose, respectively. These mannotrioses were iso-
latedonaCOSMOSILSugar-Dcolumn (NacalaiTesque)using an
isocratic solvent composed of 65% MeCN and 35% H2O. NMR
andMS spectra of these compoundswere in good agreementwith
those reported for closely related compounds (29, 30).
Preparation of Man3GlcNAc and Man6(GlcNAc)2-Asn—
Man3GlcNAc was prepared from urine of a mannosidosis
patient as described previously (31). Briefly 10 ml of urine
containing 10 mg of creatinine was concentrated to 1 ml and
centrifuged for 20 min at 3,000 rpm. The supernatant was
subjected to Bio-Gel P-4 (200–400 mesh) column chromatog-
raphy (2.6  97 cm). The column was eluted with water con-
taining 0.002% phenylmercuric nitrate, and the hexose content
in each fractionwas analyzedwith phenol-sulfuric acid reagent.
Fractions between Man2GlcNAc and Man4GlcNAc were
pooled, sequentially subjected to Bio-Gel P-4 (under 400mesh)
column chromatography (2 100 cm) at 55 °C, and elutedwith
distilledwater bymonitoringwith a refractometer. The fraction
corresponding to Man3GlcNAc was collected, and the struc-
FIGURE1.Chemical structuresofMan9(GlcNAc)2.The individual carbohydrate residuesofMan9(GlcNAc)2 are
labeled. The D1 arm of Man9(GlcNAc)2 is colored in green.
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ture of Man3GlcNAc was identified as Man--1,2-Man--1,3-
Man--1,4-GlcNAc by methylation analysis and sequential
exoglycosidase digestion using Man132-specific Aspergillus
saitoi -mannosidase, jack bean -mannosidase, and snail
-mannosidase. The yield was 1100 nmol. Man6(GlcNAc)2-
Asnwas prepared fromovalbumin as described previously (32).
Protein Expression and Purification—The DNA fragment
for residues 51–301, which correspond to the CRD and part
of the stalk domain of canine VIP36, was cloned into the
BamHI and EcoRI sites of pGEX4T-1 plasmid (GE Health-
care). The recombinant VIP36 was expressed in Escherichia
coli BL21(DE3). Cells were harvested after induction with 0.1
mM isopropyl -D-thiogalactoside (Wako) for 15 h at 20 °C
and lysed by sonication in phosphate buffered saline buffer
containing 2 mM CaCl2. The cell lysate was loaded on a glu-
tathione-Sepharose 4B column (GE Healthcare). The gluta-
thione S-transferase (GST) fusion protein was eluted by gluta-
thione (Wako) and cleaved by thrombin protease (GE
Healthcare). The cleaved proteins were passed through a gluta-
thione-Sepharose 4B column to remove GST protein and fur-
ther purified by a benzamidine-Sepharose 4FF column (GE
Healthcare) to remove the thrombin protease. The purified
protein was dialyzed against 10 mM MES (pH 6.5) and 2 mM
CaCl2.
Crystallization and X-ray Data Collection—Initial crystalli-
zation conditions were screened using the Large Scale Protein
Crystallization andMonitoring System (PXS) (33). The crystal-
lization conditions of VIP36 in its Ca2-bound form were
obtained in a buffer containing 18 mg ml1 protein, 15% (w/v)
polyethylene glycol 4000, 1.5 M NaCl, and 0.1 M MES (pH 6.5)
with incubation at 277K for 4 days. For themetal free-form, the
Ca2-bound crystal was soaked with this buffer containing 10
mM EDTA to remove Ca2. The crystal of Ca2.Man-bound
VIP36was obtained by soaking theCa2-bound crystalwith the
buffer containing 50 mM D-mannose (Sigma). The Ca2.Man2-
bound VIP36 was co-crystallized in a buffer containing 10 mg
ml1 protein, 3.4 mM 2-mannobiose (Sigma), 5% (w/v) poly-
ethylene glycol 4000, 0.3 MMgCl2, and 0.1 MMES (pH 6.5) with
incubation at 277 K for 1 week. On the other hand, the
Ca2.Man3GlcNAc-bound VIP36 was co-crystallized in a
buffer containing 10 mg ml1 protein, 3.4 mM Man3GlcNAc,
10% (w/v) polyethylene glycol 4000, and 0.4 M imidazolemalate
(pH 6.0) with incubation at 277 K for 3 weeks. Despite the
extensive co-crystallization with Man3GlcNAc the electron
density map did not show any interaction with the GlcNAc
moiety; only the Man3 portion was recognized by VIP36. Data
sets of themetal-free andCa2.Man2- andCa2.Man3GlcNAc-
bound forms were collected under cryogenic conditions with
crystals soaked with a cryoprotectant buffer containing 20%
(v/v) glycerol. The Ca2-, Ca2.Man-bound crystals were
soakedwith a buffer containing 2.5 M LiCl instead of 1.5 MNaCl
for data collection under cryogenic conditions. The diffraction
data were processed using HKL2000 (34). The metal-free and
Ca2-, Ca2.Man-, and Ca2.Man2-bound crystals belong to
space group C2 with two molecules per asymmetric unit. In
contrast, the Ca2.Man3GlcNAc-bound crystal belongs to
space group P212121 with five molecules per asymmetric unit.
The crystallographic parameters of VIP36 are shown inTable 1.
Structure Determination and Refinement—The crystal struc-
ture of VIP36was solved by themolecular replacementmethod
using the program MOLREP (35) with the Ca2-bound
ERGIC-53 (Protein Data Bank code 1R1Z) (23) as a search
model. The refinement procedures were carried out with Crys-
tallography and NMR System (CNS) (36) and REFMAC5 (37).
Model fitting to the electron densitymaps was performedman-
ually using Coot (38). The stereochemical quality of the final
models was assessed by PROCHECK (39). Final refinement sta-
tistics are summarized in Table 1. Figures were prepared using
GRASP (40), LIGPLOT, (41), and PyMOL (42).
Computer-aided Model Building—The model of VIP36
Man8(GlcNAc)2-Asn complex was built using coordinates of well
ordered high mannose type glycans on glycoprotein crystal
structures (human pancreatic -amylase (Protein Data Bank
code 1BSI), Erythrina corallodendron lectin (Protein Data
Bank code 1LTE), and exo-(1,3)--glucanase (Protein Data
Bank code 1H4P)) and mannosyl ligand-bound VIP36 struc-
tures. The corresponding glycan residues were superim-
posed on each other, and appropriate coordinates were used
as follows: Asn-GlcNAc(1), Protein Data Bank code 1BSI;
GlcNAc(2), Protein Data Bank code 1LTE; Man(3)-Man(4)-
Man(C), Man3GlcNAc-bound VIP36; Man(D1), Man2-
bound VIP36;Man(4)-(Man(A))-Man(B)-Man(D3), Protein
Data Bank code 1H4P; VIP36, Man2-bound form. Based on
the above model and human salivary -amylase (Protein
Data Bank code 1SMD) structures, the complex model of
VIP36rat salivary -amylase carrying Man8(GlcNAc)2 was
built. The salivary -amylase was docked onto the
VIP36Man8(GlcNAc)2-Asn complex model through super-
imposition with an N-glycosylation site (Asn461) of the sali-
vary -amylase and the asparagine residue of the high man-
nose type glycan bound with VIP36.
Surface Plasmon Resonance (SPR) Analysis—SPRmeasure-
ments were carried out at 25 °C using a Biacore 2000 (Bia-
core) equipped with a CM5 sensor chip. GST-VIP36 (resi-
dues 51–322) was purified by affinity chromatography using
glutathione-Sepharose 4B and benzamidine-Sepharose 4FF
columns. The purified protein was immobilized on the flow
cell using the amine coupling method. Various concentra-
tions of mannotrioses (Man--1,2-Man--1,2-Man, Man--
1,2-Man--1,3-Man, and Man--1,2-Man--1,6-Man) and
Man6(GlcNAc)2-Asn in sample buffer (50 mM HEPES (pH
6.0) and 1 mM CaCl2) were injected over the flow cells at a
flow rate of 20 l/min using HBS-P buffer (10 mM HEPES
(pH 7.4), 150 mM NaCl, and 0.005% surfactant P20) as the
running buffer.
RESULTS
Crystallization and Overall Structure of Exoplasmic/Lumi-
nal Domain of VIP36—The exoplasmic/luminal domain (resi-
dues 51–301) of VIP36, corresponding to the CRD and part of
the short stalk domain, was crystallized. Despite extensive crys-
tallization screening, diffraction quality crystals of the CRD
(residues 51–278) alone could not be produced. The crystal
structure of the exoplasmic/luminal domain of Ca2-bound
VIP36 was solved by the molecular replacement method using
the Ca2-bound ERGIC-53 CRD (Protein Data Bank code
Structure of VIP36Mannosyl Ligand Complex
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1R1Z) (23) as a search model. The crystal belongs to space
group C2 with two molecules (A and B) per asymmetric unit.
Both VIP36 molecules are related by2-fold symmetry, form-
ing a pseudo-homodimer. However, gel filtration data demon-
strate that this protein is monomeric in solution (supplemental
Fig. 1).
To obtain crystals of mannose-bound VIP36, the Ca2-
bound crystals were soaked in a solution containingmannose in
molar excess. The Man2-bound form was obtained by co-crys-
tallization. To obtain the metal-free form, the Ca2-bound
crystal was soaked with buffer containing 10 mM EDTA. Crys-
tallization of VIP36 in the absence of Ca2 was not successful.
Following treatment with EDTA the Ca2 is completely absent
from molecule B, whereas approximately half of the Ca2 ions
are removed frommolecule A. In the C2 crystal form, crystalli-
zation of VIP36 in complex with longer oligomannoses was not
successful due to the crystal packing around the ligand-binding
site. To find other crystal forms, we therefore carried out crys-
tallization screening in the presence of Ca2 and longer oligo-
mannoses, Man--1,2-Man--1,2-Man, Man--1,2-Man--
1,3-Man, Man3GlcNAc, and Man6(GlcNAc)2-Asn. Diffraction
quality crystals were obtained from co-crystallization with the
Man3GlcNAc alone. The crystal belongs to space group
P212121 with five molecules (A, B, C, D, and E) per asymmetric
unit. The structure has theMan--1,2-Man--1,3-Manmoiety
in molecules A and B, whereas the GlcNAc moiety is disor-
dered. In contrast, only onemannose residue is ordered inmol-
ecule C, and all the carbohydrate residues are disordered in
molecules D and E. The dimer interfaces of the P212121 crystal
form are different from that of the C2 crystal form, suggesting
that VIP36 is monomeric.
TheCRD of VIP36 has an overall globular shape composed
of a -sandwich of two antiparallel -sheets and is composed
of 17 -strands and three 310 helices, each with a single turn
(Fig. 2A). The -sandwich comprises a seven-stranded (2-
5-14-7-8-9-10) concave -sheet and a six-stranded
(1a,b-15-6-11-12-13a) convex -sheet in a variation
of the jelly roll fold. The -strands are numbered according
to the secondary structure numbering scheme of ERGIC-53
(22). A -hairpin (strands 3 and 4) is inserted between 2
and 5. Residues Cys202 (strand 10) and Cys239 (strand
13a) form a disulfide bond. The stalk domain is composed
of a -strand (16), a short -helix (H4), and one turn of a 310
helix (H5). The 16 forms a -sheet with 13b on the face of
the protein opposite to the ligand-binding site between the
concave and convex -sheets. The stalk domain (residues
TABLE 1
Data collection and refinement statistics of VIP36
Data set
VIP36 VIP36Ca2 VIP36Ca2Man VIP36Ca2Man2 VIP36Ca2Man3GlcNAc
Crystallographic data
Space group C2 C2 C2 C2 P212121
Unit cell
a/b/c (Å) 171.0/45.2/117.1 170.1/45.4/116.1 171.2/45.0/117.0 171.2/45.5/117.4 57.2/151.2/177.1
// (°) 90.0/132.6/90.0 90.0/131.5/90.0 90.0/131.9/90.0 90.0/132.7/90.0 90.0/90.0/90.0
Data processing statistics
Beam line PF-AR NW12A PF-AR NW12A PF-BL5A PF-BL5A PF-BL5A
Wavelength (Å) 1.0000 1.0000 1.0000 1.0000 1.0000
Resolution (Å)a 50-2.10 (2.18-2.10) 50-1.80 (1.86-1.80) 50-1.80 (1.86-1.80) 50-1.65 (1.71-1.65) 50-2.50 (2.59-2.50)
Total reflections 128,308 228,854 191,856 283,509 350,729
Unique reflections 38,945 62,420 62,207 80,482 54,228
Completeness (%)a 93.7 (78.9) 97.8 (97.1) 96.1 (84.5) 98.4 (91.1) 99.9 (100.0)
Rmerge (%)a 8.3 (31.4) 5.9 (38.5) 9.9 (28.2) 5.1 (28.6) 13.3 (37.6)
I/(I)a 13.4 (3.7) 14.6 (3.1) 9.1 (2.9) 14.4 (3.4) 8.8 (5.8)
Refinement statistics
Resolution (Å) 20-2.10 20-1.80 20-1.80 20-1.65 20-2.50
Rwork 22.5 20.5 20.6 19.9 22.1
Rfree 27.8 24.1 24.5 22.8 27.9
r.m.s.b deviation from ideal values
Bond length (Å) 0.012 0.012 0.011 0.011 0.013
Angle distance (Å) 1.34 1.33 1.33 1.32 1.41
Ramachandran plot (%)
Most favored 87.5 88.1 89.0 88.5 86.6
Additionally allowed 11.8 11.4 10.5 10.8 13.3
Generously allowed 0.7 0.5 0.5 0.7 0.1
Disallowed 0 0 0 0 0
Number of molecules and atoms
Protein atoms 3,913 3,957 3,974 4,071 9,617
Water molecules 194 421 429 418 66
Ca2 ions 0.5 2 2 2 5
Cl ions 4 11 13 8
Glycerol atoms 18 12
Sugar atoms 24 46 80
Average B-values (Å2)
Protein atoms 32.3/46.6 21.2/28.1 24.4/29.5 22.9/32.0 24.0/28.9/23.8/26.5/36.7
Water molecules 36.5 29.9 32.9 33.4 20.6
Ca2 ions 33.4 23.5 21.8 20.0 25.4
Cl ions 44.0 29.4 32.0 33.5
Glycerol atoms 47.9 33.1
Sugar atoms 23.0 27.6 39.5
a Values in parentheses are for the highest resolution shell.
b Root mean square.
Structure of VIP36Mannosyl Ligand Complex
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289–301) contributes to an extensive crystal contact (Fig. 2A
and supplemental Fig. 2) that explains the successful crystal-
lization of this construct.
Ca2-binding Site and Its Structural Changes in VIP36 CRD—
The Fo Fc electron density map of VIP36 shows one promi-
nent peak corresponding to a Ca2 ion coordinated between
two loops, which are termed Loop 1 (between 8 and 9) and
Loop 2 (between 9 and 10). The side-chain oxygen atom of
Asp162 (O-1 and O-2), Asn166 (O-1), and Asp193 (O-2);
main-chain carbonyl oxygen atoms of Tyr164 (O); and two
watermolecules termedW1 andW2 (O) are coordinated to the
Ca2 with distances of 2.4–2.5 Å (Fig. 3).
Upon Ca2 binding, significant conformational changes
occur around Loops 1 and 2 (Fig. 3). Large movements of the
Ca2-coordinating and neighboring atoms are observed for
the O-2 of Asp131, O-1 of Asn166, and N-1 of His190. The
distances are 1.7, 1.6, and 4.0 Å,
respectively. The O-2 of Asp131
and N-1 atom of His190 form
hydrogen bonds with Ca2-coordi-
natingwatermoleculesW1andW2,
respectively, whereas the O-1 of
Asn166 is directly coordinated with
Ca2. As we will describe further
below, these residues bind the car-
bohydrate moiety in the presence of
Ca2 suggesting a mechanism for
the Ca2-dependent carbohydrate
binding of VIP36.
Specific Binding of VIP36 to D1
Arm of High Mannose Type Gly-
can—Previous studies have sug-
gested that VIP36 CRD recognizes
D1 arm, Man--1,2-Man--1,2-
Man residues of high mannose type
glycans (19, 20). In fact, we observed
using SPR analysis that VIP36 has
higher affinity for Man--1,2-Man-
-1,2-Man oligosaccharide (corre-
sponding to Man(D1)-Man(C)-
Man(4) of the D1 arm) than for
Man--1,2-Man--1,3-Man (Fig.
4). No interaction was observed
between VIP36 and Man--1,2-
Man--1,6-Man. In addition, we
observed that Ca2 ion is required
for the interaction between VIP36
and Man6(GlcNAc)2-Asn (supple-
mental Fig. 3). The calculated disso-
ciation constant betweenVIP36 and
Man6(GlcNAc)2-Asn in the pres-
ence of 1 mM Ca2 was 70 M. On
the other hand, no interaction was
observed in the presence of 5 mM
EDTA.
Structure of VIP36 in Complex
with Ca2 and Man—In the struc-
ture of VIP36 in complex with Ca2
and mannose, the mannose is located in a pocket neighboring
the Ca2-binding site on the concave -sheet and has well
defined electron density (Fig. 5A). The mannose-binding site
(also called the “primary binding site” hereafter) comprises 7
and Loops 1, 2, and 3. A number of specific contacts can be seen
between the protein and the ligand. The mannose is bound by
Asp131 (O-1 and O-2), Asn166 (N-2), His190 (N-2), Gly260
(N), Asp261 (N), and Leu262 (N) through hydrogen bonds in the
complex (Fig. 5D). Incidentally the side-chain positions of
Asp131, Asn166, and His190 in the primary binding site are sta-
bilized by Ca2.
Structure of VIP36 in Complex with Ca2 and Man2—The
Man--1,2-Man residues have extremely well defined electron
density in the structure of VIP36Man2 complex (Fig. 5B). The
4-OH and 6-OH groups of the non-reducing mannose residue
make hydrogen bonds with Ser96 (O) and Asp261 (O-1),
FIGURE2.Overall structureof theexoplasmic/luminaldomainofVIP36.Ribbonmodels of theVIP36 (Man2-
bound form,molecule A) are shown inA. The secondary structures are highlighted (-strands belonging to the
concave -sheets, yellow; -strands belonging to convex -sheets, blue; -strands belonging to -hairpin,
cyan; -strands belonging to the short -sheet formed between the stalk domain and one of the loops of the
CRD,magenta; helices, red), and the loopsof theCRDand stalk domain are coloredgray andgreen, respectively.
The bound Ca2 is shown as a pink sphere. The bound oligomannoses are superimposed from the VIP36
complex structures withMan--1,2-Man andMan--1,2-Man--1,3-Man and are shown as a green stickmodel.
The reducing-endmannose residue in theMan2-bound form is omittedbecause its position is almost the same
as that of the Man3GlcNAc-bound form. Positions of Loops 1, 2, and 3, which are bound to the oligomannose,
are indicated. The surface models (B) are shown in the same orientations as in A and colored according to
the electrostatic surface potential (blue, positive; red, negative; scale from10 to10 kT/e).
FIGURE 3. Ca2-binding site and its conformational changes upon Ca2 binding of VIP36. The Ca2-
bound (moleculeA) andmetal-free (moleculeB) structures are shown in stereoandcolored in yellow andgreen,
respectively. Residues coordinating Ca2 and those with notable conformational changes are shown in ball-
and-stickmodels.Watermolecules are labeledW1 andW2. Ca2-coordinating bonds are solid lines, and hydro-
gen bonds are dotted lines.
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respectively (Fig. 5E). In contrast, the hydrogen bond between
the 6-OH group and Asp261 (O-1) is not observed in molecule
B (supplemental Fig. 4A). The binding site of the reducing-end
mannose residue of Man2 is almost the same as the primary
binding site (Fig. 5, D and E).
Structure of VIP36 in Complex with Ca2 andMan3GlcNAc—
In the structure of VIP36 with Man3GlcNAc, the Man3 moiety
is ordered, whereas the GlcNAc moiety is disordered. The
Man--1,2-Man--1,3-Man residues have defined electron
density (Fig. 5C). The binding site of the non-reducing man-
nose residue ofMan3GlcNAc is almost the same as the primary
binding site (Fig. 5,D and F). The 6-OH group of the 1–2- and
1–3-linked mannose residue makes hydrogen bonds with
Tyr164 (O) and Asn166 (O) (Fig. 5F). The 1–3- and 1–4-
linkedmannose residue is recognized byAsp261 (O-1) through
a hydrogen bond,whereas the hydrogen bond is not observed in
molecule B (supplemental Fig. 4B).
DISCUSSION
Many lectins, such as mannose-binding proteins and the
asialoglycoprotein receptors, achieve higher affinity and selec-
tivity through oligomerization of their CRDs (43). For instance,
ERGIC-53 and Emp46/47p are known to form oligomeric com-
plexes through the putative coiled-coil region in the stalk
domain (15, 44, 45). On the other hand, it has been shown that
FIGURE 4. Specific binding of GST-VIP36 to the D1 arm (Man--1,2-Man-
-1,2-Man) revealed by SPR analysis. Three different mannotrioses were
added over flow cells at the indicated concentrations. Specific binding of
mannotrioses was obtained by subtracting the resonance unit (RU) value of
the GST immobilized sensor chip from the values of GST-VIP36 immobilized
sensor chips. The plots were obtained by subtracting the values measured
using the sample buffer without carbohydrates. The dose binding curves
were obtained from the resonance unit value at 200 s. Solid circle, Man--1,2-
Man--1,2-Man; open circle, Man--1,2-Man--1,3-Man; solid triangle,
Man--1,2-Man--1,6-Man.
FIGURE 5. Carbohydrate ligand-binding site of VIP36. 2Fo Fc electron density map of mannose of the Man-bound form (A), Man--1,2-Man of the
Man2-bound form (B), and Man--1,2-Man--1,3-Man of the Man3GlcNAc-bound form (C) contoured at 1.2. Secondary structures are shown as in Fig. 2A.
D, structure of mannose and Ca2-binding site of VIP36 (molecule A). E, structure of Man--1,2-Man and Ca2-binding site of VIP36 (molecule A). F, structure
ofMan--1,2-Man--1,3-ManandCa2-binding siteofVIP36 (moleculeA). Theboundcarbohydrate residuesare shownasgreen stickmodels. ResiduesofVIP36
binding to the ligands are shown in ball-and-stickmodels.
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no disulfide-linked or stable non-covalent oligomers of recom-
binant exoplasmic/luminal domain (residues 45–322) or
endogenous VIP36 could be detected by cross-linking or sedi-
mentation analysis (46). Furthermore we confirmed that the
exoplasmic/luminal domain of VIP36 (residues 51–301 and
51–322) ismonomeric in physiological solution by gel filtration
analyses (supplemental Fig. 1). Indeed the stalk domain (resi-
dues 279–322) of VIP36 is 95–162 residues shorter than those
of ERGIC-53, Emp46p, and Emp47p. The portion of the stalk
domain of VIP36 included in our construct (residues 279–301)
does not form coiled-coil structure (Fig. 2A and supplemental
Fig. 2). The short stalk domain and the absence of coiled-coil
domain suggest that VIP36 may likely function as a monomer.
It is known that leguminous lectins coordinate Mn2 and
Ca2 ions, termed S1 and S2, respectively, in their -sandwich
structures (Fig. 6, A and B) (47). The S1 ion stabilizes the
S2-binding site, and the S2 ion fixes the positions of the amino
acids that interact with the oligosaccharide ligands. In this
study, we showed that VIP36 has a
single Ca2 in the CRD structures
and that theCa2 fixes the positions
of Asp131, Asn166, and His190 that
interact with carbohydrate ligands
in the primary binding site (Figs. 3
and 5). Specifically significant con-
formational changes upon Ca2
binding take place around the Ca2
and primary carbohydrate-binding
site of VIP36 (Fig. 3). Similar but
more pronounced structural changes
of the corresponding site upon
metal binding were also observed
in concanavalin A (ConA) (48) and
ERGIC-53 (23). The Ca2 of ConA
induces large conformational
changes to stabilize the correct
geometry of the Ca2-binding site
that comprise the trans to cis
isomerization of the Ala207-Asp208
peptide bond accompanied by the
formation of the carbohydrate-
binding site (48). In VIP36 struc-
tures, such isomerization changes
were not observed. We also
observed that Ca2 is required for
interaction between VIP36 and
Man6(GlcNAc)2-Asn by SPR exper-
iments (supplemental Fig. 3). These
results explain the Ca2-dependent
carbohydrate binding of VIP36.
It was shown that ERGIC-53
contains two Ca2 ions termed
M1 and M2 (Fig. 6, C and D) and
that the M1 ion does not lie at the
same site as the S1 ion, although
M2 is located at the corresponding
S2 site (23). The Ca2 of VIP36
corresponds to the M2 site of
ERGIC-53. When the VIP36 and ERGIC-53 structures are
superimposed, the M2 metal ions overlay with a separation
that is less than 0.2 Å. Although the Ca2 of VIP36 is equiva-
lent to the M2 site of ERGIC-53, the electron density maps of
VIP36 show no peak that could be assigned as ametal ion either
at the corresponding M1 site or at any other sites within the
structure. In the Ca2-binding site (M2 and S2), the Ca2-co-
ordinating residues are structurally very well conserved except
for Asp193 in VIP36 (Fig. 6, B andD). The corresponding Asp19
(ConA) andAsp189 (ERGIC-53) residues are coordinated by the
two metal ions. In VIP36, the O-1 of Asp193 forms a hydrogen
bond with the main-chain nitrogen atom of Asp167 to stabilize
the Ca2-binding site. As a result, only one Ca2 ion fixes the
ligand binding residues in VIP36. Our crystallographic studies
also suggest that VIP36 did not bind other divalent cations,
neither Mn2 nor Mg2 (data not shown). Loop 1 of VIP36 is
two residues longer than that of ERGIC-53. Likewise the resi-
dues coordinating the M1 ion in ERGIC-53 (Asp163, Asp165,
FIGURE 6. A, overall structure of ConA monomer. A purple ribbon model of ConA (molecule A) is shown. The
boundMn2 (S1) andCa2 (S2) are shownas large gray and black spheres, respectively. B, comparisonbetween
VIP36 and ConAmetal-binding site structures. The VIP36 (molecule A) and ConA structures are colored yellow
and purple, respectively. Residues of VIP36 and ConA are labeled in black and purple, respectively. The Ca2 in
VIP36 is shown as a large pink sphere. Because the position of Ca2 at the S2 site in ConA is almost the same as
in VIP36, it is not shown.Watermolecules found in the S1 site of ConA are shown as small white spheres and are
labeled W3 and W4. C, overall structure of ERGIC-53 CRD. A cyan ribbon model of ERGIC-53 (molecule A) is
shown. TheboundCa2 is shownas largemagenta spheres (M1 andM2).D, comparisonbetweenVIP36 (yellow)
and ERGIC-53 (cyan) Ca2-binding site structures. Because the position of Ca2 at the M2 site in ERGIC-53 is
almost the same as in VIP36, it is not shown. Water molecules found in the M1 site of ERGIC-53 are shown as
small orange spheres and are labeled W5 and W6. Residues involved in the metal binding are shown as ball-
and-stickmodels.
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Asn169, Asn170, and Asp189; shown in green in supplemental
Fig. 2) are poorly conserved in VIP36. Taken together, we con-
clude that VIP36 binds only one Ca2 ion and that the single
Ca2 fixes the positions of residues involved in carbohydrate
ligand binding.
Our crystallographic studies reveal extensive interactions
between VIP36 and Man--1,2-Man--1,2-Man residues of
the D1 arm of high mannose type glycans. Based on the Man-,
Man2-, andMan3GlcNAc-bound structures, a model structure
of VIP36 in complex with Man--1,2-Man--1,2-Man--1,3-
Man (Man4) was built and then designated as Man(D1)-
Man(C)-Man(4)-Man(3), respectively (Fig. 7). The carbohy-
drate-binding site is located in a negatively charged pocket (Fig.
2B). The extended carbohydrate-binding site comprises5,7,
and Loops 1, 2, and 3. The mannose residue in the primary
binding site corresponds to theMan(C)moiety at themiddle of
the D1 arm. In addition, Asp261 is flexible in mannose recogni-
tion and can flip between Man(3) and Man(D1) depending on
the local environment (supplemental Fig. 4). The crystallo-
graphic results correlate well with
the SPR experiments (Fig. 4) and the
previous results (19, 20) that VIP36
recognizes Man--1,2-Man--1,2-
Man residues of the D1 arm of high
mannose type glycans.
Next the carbohydrate-binding
site of VIP36 was compared with that
ofConA in complexwithMan--1,3-
(Man--1,6-)Man (corresponding
to Man(3)-(Man(4))-Man(4)) (49).
Although the carbohydrate binding
specificity of VIP36 and ConA is
essentially different, the structural
conservation of ligand-binding sites
between them is observed in not only
the Man(C)-binding site but also the
Man(D1)- and Man(4)-binding sites
of VIP36 (Fig. 7C). In the Man(C)-
binding site ofVIP36, the ligandbind-
ing residues are structurally very well
conserved except for His190 in VIP36
(Fig. 7C). The corresponding main-
chain nitrogen atom of Arg228 in
ConA is bound to only the 3-OH
groupof themannose residue. Incon-
trast, N-2 of His190 in VIP36 is
bound to the 3-OHand 4-OHgroups
and acts simultaneously as hydrogen
bond donor and acceptor (Fig. 7B). In
theMan(4)-binding site, although the
carbohydrate binding loop confor-
mation of VIP36 is largely different
than that of ConA, the side-chain
position of Tyr164 is very similar to
that of Tyr12 in ConA.
When the carbohydrate-binding
site of VIP36was comparedwith the
corresponding site of ERGIC-53 in
complex with Ca2 (23), the Man4 binding residues of VIP36
are largely identical to the corresponding residues of ERGIC-53
(Fig. 7D and supplemental Fig. 2). The structural conservation
suggests that ERGIC-53 also binds the D1 arm moiety of high
mannose type glycoproteins, which is consistent with the func-
tion of ERGIC-53 as a transport lectin for high mannose type
glycoproteins. These contain Man8(GlcNAc)2 with an intact
D1 arm and are transported from the ER by the ER quality
control mechanism (2, 3). However, there are some structural
differences in the5,7, and Loops 1 and 3 regions: (i) in5 the
side-chain orientation of Ser96 of ERGIC-53 is dissimilar to that
of VIP36, (ii) the side-chain orientation of Asp129 in 7 of
ERGIC-53 is different than that of the corresponding Asp131 of
VIP36, (iii) Phe162 of ERGIC-53 is replaced by Tyr164 in VIP36,
and (iv) the Loop 3 of ERGIC-53 is positioned further away
from the ligand when compared with VIP36, and Asp261 of
VIP36 is replaced by Gly260 in ERGIC-53. Most significantly,
Tyr164 and Asp261 in VIP36 are better suited than Phe162 and
Gly260 in ERGIC-53 for binding to the Man4. In ERGIC-53, the
FIGURE 7. A, superimposition of Man-, Man2-, and Man3GlcNAc-bound forms of VIP36. The Man-, Man2-, and
Man3GlcNAc-bound forms of VIP36 (molecule A) are colored inmarine blue,white, and yellow, respectively. The
bound Man, Man2, and Man3 are shown as magenta, white, and green stick models, respectively. B, ligand
binding diagram. The model of Man--1,2-Man--1,2-Man--1,3-Man (Man4) is designated as Man(D1)-
Man(C)-Man(4)-Man(3), respectively. Hydrogen bonds are indicated with dotted arrows pointing in the direc-
tion fromdonor to acceptor.C, comparisonbetween theVIP36 (yellow) andConA (purple) carbohydrate ligand-
binding site. Residues binding to the ligands are shown in ball-and-stickmodels. D, comparison between the
VIP36 (yellow) and ERGIC-53 (cyan) carbohydrate ligand-binding site. The model of Man4 is shown as a green
stick model. Residues of VIP36 binding to the ligands and the corresponding ones in ERGIC-53 are shown in
ball-and-stickmodels.
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presumptive weak interactions between ERGIC-53 and carbo-
hydrate ligands might be compensated by the oligomerization
of the CRDs.
To demonstrate that the crystal structure strictly represents
the complex formed in solution, we simulated a complexmodel
of Man8(GlcNAc)2-Asn and VIP36 (Fig. 8A). In this model,
there are no significant steric clashes between high mannose
type N-glycan and VIP36. The monomeric VIP36 seems to
accommodate the glycan along an extended ligand-binding
site. Kamiya et al. (20) have suggested thatVIP36 recognizes the
D1 arm and showed thatmannose trimming andmonoglucosy-
lation of the D1 arm resulted in significant reduction in affinity
for VIP36 CRD using frontal affinity chromatography analysis.
When a glucose residue is modeled into the VIP36Man4 struc-
ture at the Man(D1) position through 1–3 linkage, a steric
hindrance occurs between the glucose andGlu98 of VIP36 (data
not shown). In addition, we have shown that VIP36 recognizes
the D1 arm, Man--1,2-Man--1,2-Man, using SPR analysis
(Fig. 4) and that Asp131 of VIP36 plays an essential role in bind-
ing 35S-labeled secretory glycoproteins (13). Kawasaki et al. (21)
have also shown that Asp131 of VIP36 was involved in ligand
binding using a flow cytometry-based method. On the other
hand, it was shown that Asp121, Asn156, and His178 of human
ERGIC-53, which correspond to Asp131, Asn166, and His190 of
VIP36, are involved with binding to mannose and its cargo gly-
coprotein, cathepsin Z-related protein (15, 18, 50). From these
observations, we conclude that the interaction between VIP36
and high mannose type glycans in solution is also achieved
through interactions between these amino acid residues and
the D1 arm.
It has been shown that VIP36 recycles between the ER and
the Golgi complex (9–11). To date, however, there is no obvi-
ous evidence that VIP36 is involved in retrograde transport of
glycoproteins from the Golgi complex to the ER. On the other
hand, we revealed that VIP36 localizes in the trans-Golgi net-
work (12) and is involved in secretion of high mannose type
glycoproteins clusterin and -amylase (13, 14). It has been gen-
erally known that the D1 arm is trimmed by cis-Golgi manno-
sidase I to formMan5(GlcNAc)2 in the cis-Golgi. The carbohy-
drate structure has a lower affinity for VIP36 (19, 20). In this
study, we have shown that VIP36 specifically binds theMan--
1,2-Man--1,2-Man residues of the D1 arm of high mannose
type glycan. Taken together, VIP36 might be involved in anter-
ograde transport of certain glycoproteins carrying high man-
nose type glycan with the D1 arm from the ERGIC via the Golgi
complex to the plasma membrane by protecting the D1 arm
against trimming by cis-Golgi mannosidase I. Although it is not
known whether or not high mannose type glycan of rat salivary
-amylase has the D1 arm, a possible model for binding
between VIP36 and salivary -amylase carrying high mannose
type glycan (Man8(GlcNAc)2) in rat parotid acinar cells is
shown (Fig. 8B).
In summary, we determined the first complex structure of the
exoplasmic/luminal domain of the transport lectin VIP36 and
Ca2 andMan,Man2, andMan3GlcNAc,which are part of theD1
arm of high mannose type glycans. Our results provide structural
insights into the mechanism of recognition of high mannose type
glycoproteins byVIP36 in aCa2-dependent andD1 arm-specific
manner. Further biochemical analysis such as subcellular localiza-
tion of VIP36 on a wide variety of cells and identification of its
cargoglycoproteins togetherwith thedetailedcarbohydrate struc-
tureswill provide further insight into themechanismofhighman-
nose type glycoprotein transport by VIP36.
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FIGURE 8.Model for binding betweenVIP36 andhighmannose type glycan (Man8(GlcNAc)2-Asn). A, the highmannose type glycan is indicated by a stick
model. In the oligosaccharide, the part determined in this study is colored in green. The modeled D2 and D3 arms and N-linked chitobiose moiety of the high
mannose type glycan are shown in purple. The types of glycosidic linkages are also indicated. The individual carbohydrate residues of Man8(GlcNAc)2-Asn are
shown as in Fig. 1. Residues involved in the ligand binding are shown as ball-and-stick models. B, model for binding between VIP36 and salivary -amylase
carrying Man8(GlcNAc)2 in rat secretory vesicles.
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 S1
Supplementary Figure Legends 
 
Supplementary Fig. 1.  Gel filtration chromatography of VIP36. Purified exoplasmic/lumenal 
domain of VIP36 (residues 51-301 and 51-322) were used for the estimation of the molecular 
masses in solution. The samples (0.5 ml, 1.2 mg/ml) were loaded to Superdex 75 10/300 GL 
column (GE Healthcare Bio-sciences), with 10 mM MES (pH 6.0), 150 mM NaCl, and 2 mM 
CaCl2 at a flow rate of 0.25 ml/ml. For calibration of the column the following size markers 
(Sigma) were used: bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa), cytocrome c 
(12.4 kDa), aprotinin (6.5 kDa). The elution profiles were recorded as absorbance at 280 nm. 
The VIP36 were eluted from the column at molecular masses of ~29 kDa, suggesting that 
VIP36 exists as a monomer in solution. 
 
Supplementary Fig. 2.  Alignment of amino acid sequences of canine VIP36, rat ERGIC-53, 
human VIPL and ERGL, yeast Emp46p and Emp47p. Red, blue and green letters indicate 
conserved residues among all the transport lectins, conserved residues among the animal 
transport lectins, Ca2+-coordinating residues in the ERGIC-53, respectively. Blue, green, red, 
yellow and magenta asterisks indicate Ca2+-coordinating residues, Man(D1)-, Man(C)-, Man(4)- 
and Man(3)-binding residues in VIP36, respectively. Secondary structures of VIP36 are shown 
above the amino acid sequences and are colored as in Figure 2A. The sequence identity values 
between VIP36 and other L-type lectins are as follows: versus ERGIC-53 33.5%, versus 
Emp46p 18.0%, and versus Emp47p 21.2%. The root mean square deviation values are as 
follows: versus ERGIC-53 (PDB entry 1R1Z) is 0.84 Å, versus Emp46p (PDB entry 2A6V) is 
1.19 Å and versus Emp47p (PDB entry 2A6Y) is 1.09 Å. The cores of these structures share 
essentially the same fold. 
 
Supplementary Fig. 3.  Ca2+-dependent binding of GST-VIP36 to Man6GlcNAc2-Asn revealed 
by SPR analysis. Sensorgrams of Man6GlcNAc2-Asn with GST-VIP36 in the presence of 1 mM 
CaCl2 (A) and in the presence of 5 mM EDTA (B). Specific binding of Man6GlcNAc2-Asn were 
obtained by subtracting the resonance unit (RU) value of the GST immobilized sensor chip from 
the values of GST-VIP36 immobilized ones. The plots were obtained by subtracting the values 
measured using the sample buffer without Man6GlcNAc2-Asn. The dose-binding curves were 
obtained from the RU value at 200 sec, and shown in (C). In panel (C), solid and open circles 
indicate the presence of 1 mM CaCl2 and 5 mM EDTA, respectively. 
 
Supplementary Fig. 4.  Superimposition of molecules A and B of Man2 (A)- and Man3GlcNAc 
(B)-bound forms of VIP36. Molecules A and B are colored in yellow and grey, respectively. 
 S2
Residues interacting with carbohydrates are shown as ball-and-stick models. The carbohydrates 
bound in molecules A and B are shown as green and black stick models, respectively. 
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